- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02763995
Pharmacotherapy Follow-up in Older HIV-infected Patients
Pharmacotherapy Follow-up in Older HIV-infected Patients: Impact on Cardiovascular Risk and Quality of Life
Cardiovascular diseases (CVD) are the main cause of death in Spain. In HIV patients, the uncontrolled viral replication, antiretroviral therapy (ART) and coinfections contribute to develop metabolic diseases and increase the prevalence of risk factors for CVD. These patients are aging which results in a higher probability of comorbidities, increased number of medications, possibility of having a negative outcome associated with medication (NOM) and increased cardiovascular risk (CVR). Various studies have established that pharmaceutical care (PC) results in better control of cardiovascular risk factors.
The purpose of this study is to evaluate the impact of pharmaceutical care achieved through pharmacotherapy follow-up on cardiovascular risk and health related quality of life (HRQoL) of HIV patients older than 50.
Descripción general del estudio
Descripción detallada
Quasi-experimental clinical study, pre-post intervention, performed with one patient cohort.
Study will be carry out at a tertiary hospital. The population will be constituted of patients who receive care from the outpatient department of the pharmacy service in use of antiretroviral therapy.
Variables will be obtained from patients' clinical histories, from dispensing records and through interviews with patients.
Main variables:
- cardiovascular risk estimated according to Systematic Coronary Risk Evaluation (SCORE) and Registre Gironí del Cor (REGICOR) equations
- HRQoL measured by the Short-Form 36-Item Health Survey (SF-36) and Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaires.
Other variables: sociodemographic, clinical, pharmacological, related to CVR, related to NOM and to the interventions.
Interventions will be performed every two months until complete 12 months of follow-up. Pharmacotherapy follow-up will be conducted according to the Dader method. The interventions will be health education for lifestyle modification, improve adherence and aimed to the resolution of NOM and drug-related problems.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Granada, España
- Hospital Universitario Virgen de las Nieves
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- patients older than 50 years
- in use of antiretroviral therapy
- cardiovascular risk ≥2%, estimated by the SCORE equation
- accept to participate in the research through the signature of a written informed consent
Exclusion Criteria:
- patients with neurodegenerative deficit or HIV dementia
- participants in clinical trials
- non signature of a written informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Pharmaceutical care
Dader method.
Health education for lifestyle modification.
Improve adherence.
Resolution of negative outcome associated with medication.
|
This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Cardiovascular risk estimation
Periodo de tiempo: Baseline and 12 months
|
Change in cardiovascular risk estimated by SCORE equation will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
Cardiovascular risk estimation
Periodo de tiempo: Baseline and 12 months
|
Change in cardiovascular risk estimated by REGICOR equation will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
Health-related quality of life
Periodo de tiempo: Baseline and 12 months
|
Change in health-related quality of life measured by SF-36 questionnaire will be evaluated after one year of Pharmaceutical Care.
|
Baseline and 12 months
|
Health-related quality of life
Periodo de tiempo: Baseline and 12 months
|
Change in health-related quality of life measured by MOS-HIV questionnaire will be evaluated after one year of Pharmaceutical Care.
|
Baseline and 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Systolic and diastolic blood pressure
Periodo de tiempo: Baseline and 12 months
|
Change in systolic and diastolic blood pressure will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
Total cholesterol levels
Periodo de tiempo: Baseline and 12 months
|
Change in total cholesterol levels will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
High-density lipoprotein (HDL-c) levels
Periodo de tiempo: Baseline and 12 months
|
Change in HDL-c will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
Low-density lipoprotein (LDL-c) levels
Periodo de tiempo: Baseline and 12 months
|
Change in LDL-c will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
Triglycerides levels
Periodo de tiempo: Baseline and 12 months
|
Change in triglycerides levels will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
Glucose levels
Periodo de tiempo: Baseline and 12 months
|
Change in glucose levels will be evaluated after one year of Pharmaceutical Care
|
Baseline and 12 months
|
Number of patients with smoking cessation
Periodo de tiempo: Baseline and 12 months
|
Patients that achieve smoking cessation after one year of Pharmaceutical Care
|
Baseline and 12 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Elza Aparecida M Domingues, MSc, Universidad de Granada
- Director de estudio: Miguel Angel Calleja Hernandez, PhD, University Hospital Virgen de las Nieves
- Director de estudio: Monica Ferrit Martin, PhD, University Hospital Virgen de las Nieves
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- University of Granada
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre VIH
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán
Ensayos clínicos sobre Pharmaceutical care
-
Silke Wiegand-Grefe, Prof. Dr.Charite University, Berlin, Germany; Hannover Medical School; University Hospital... y otros colaboradoresActivo, no reclutandoEnfermedades rarasAlemania
-
Elizabeth Glaser Pediatric AIDS FoundationUnited States Agency for International Development (USAID); Ministry of Health...TerminadoInfecciones por VIHSuazilandia
-
University Health Network, TorontoReclutamientoLinfoma | Trastornos linfoproliferativos | Etapa I del cáncer de mama | Cáncer de mama en estadio II | Cáncer colorrectal en estadio II | Cáncer colorrectal en estadio III | Etapa III del cáncer de mama | Cáncer colorrectal Etapa I | Cáncer de cabeza y cuello estadio III | Cáncer de mama, estadio 0 | Cáncer... y otras condicionesCanadá
-
KintoAlzheimer's AssociationTerminadoDemencia | Enfermedad de Alzheimer | Enfermedad de cuerpos de Lewy | Demencia frontotemporal | Demencia vascular | Demencia mixtaEstados Unidos
-
Emory UniversityFoundation for Physical Therapy, Inc.Terminado
-
Southeast University, ChinaChinese Academy of SciencesTerminadoSepticemia | Shock séptico | La comunidad adquirió neumoníaPorcelana
-
University of AlbertaUniversity Hospital FoundationTerminado
-
Institute of Mental Health, SingaporeNational Healthcare Group, SingaporeReclutamientoDemencia | Carga del cuidador | Salud digitalSingapur
-
The Third Xiangya Hospital of Central South UniversityAún no reclutandoEnfermedad de Charcot-Marie-Tooth (CMT)
-
University of Michigan Rogel Cancer CenterReclutamiento